title: Plasma, intestine and tumor levels of 5-fluorouracil in mice bearing L1210 ascites tumor following oral administration of 5-fluorouracil, UFT (mixed compound of tegafur and uracil), carmofur and 5'-deoxy-5-fluorouridine.
abstract: Several 5-fluorouracil (5-FU) derivatives, 1-hexylcarbamoyl-5-fluorouracil (HCFU), 5'-deoxy-5-fluorouridine (5'-DFUR) and UFT (mixed compound of tegafur and uracil), have been developed and clinically widely used. However, comparative pharmacokinetic studies of the parent compound and other fluorinated drivatives have not been precisely reported. The dosage of the oral clinical use for human cancer of 5-FU, HCFU, 5'-DFUR and UFT as tegafur (FT) is 200-300mg/d, 600mg/d, 800-1,200mg/d and 300-600mg/d respectively. These amounts of the drugs are almost equimolar. Previously, we reported the effect of oral equimolar administration of each four drugs on thymidilate synthase activity, deoxyribonucleotide metabolism and cell cycle progression in L1210 ascites tumor. (1,2) In this study, we examined the antitumor effect and 5-FU concentration in the plasma, intestine and tumor after oral equimolar administrations of each drug using BDF1 mice bearing L1210 ascites tumor. In our study, UFT showed the best life prolongation among these four drugs. The intestine 5-FU level was highest by treatment with 5-FU during the initial 4 h. The plasma 5-FU level was highest by treatment with HCFU for 4 h. But the tumor 5-FU level was highest by treatment with UFT over the 24 h. In spite of the high plasma 5-FU concentration after the treatment with HCFU, the 5-FU concentration in the tumor was below the detectable level until 24 h. These findings suggested that the highest specific accumulation of 5-FU in tumor cells may explain the best therapeutic results of UFT.
authors.affiliation: Department of Pharmacy, Yokkaichi Social Insurance Hospital, Yokkaichi, Japan. ooii@mvc.biglobe.ne.jp
authors.forename: A
authors.initials: A
authors.lastname: Ooi
authors.forename: T
authors.initials: T
authors.lastname: Ohkubo
authors.forename: M
authors.initials: M
authors.lastname: Higashigawa
authors.forename: H
authors.initials: H
authors.lastname: Kawasaki
authors.forename: H
authors.initials: H
authors.lastname: Kakito
authors.forename: Y
authors.initials: Y
authors.lastname: Kagawa
authors.forename: M
authors.initials: M
authors.lastname: Kojima
authors.forename: M
authors.initials: M
authors.lastname: Sakurai
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000970:Antineoplastic Agents / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy / Q000378:metabolism*; D004338:Drug Combinations; D005467:Floxuridine / Q000493:pharmacokinetics / Q000627:therapeutic use; D005472:Fluorouracil / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D007413:Intestinal Mucosa / Q000378:metabolism*; D007939:Leukemia L1210 / Q000188:drug therapy / Q000378:metabolism*; D008297:Male; D051379:Mice; D005641:Tegafur / Q000493:pharmacokinetics / Q000627:therapeutic use; D014498:Uracil / Q000493:pharmacokinetics / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D004338:Drug Combinations; C096910:UFT(R) drug; D005467:Floxuridine; D005641:Tegafur; D014498:Uracil; C017367:carmofur; D005472:Fluorouracil; C025034:doxifluridine